Renal replacement therapy in the treatment of confirmed or suspected inborn errors of metabolism.
OBJECTIVE
Analysis of mortality and risk factors for mortality in the use of renal replacement therapy to correct metabolic disturbances associated with confirmed or suspected inborn errors of metabolism.


METHODS
A retrospective review of an institutional review board-approved pediatric acute renal failure data base at the University of Michigan. Eighteen patients underwent 21 renal replacement therapy treatments for metabolic disturbances caused by urea cycle defects (n = 14), organic acidemias (n = 5), idiopathic hyperammonemia (n = 1), and Reye syndrome (n = 1).


RESULTS
There were 14 boys (74%) and 4 girls (26%), with a mean age and weight of 56.2 +/- 71.0 months and 18.5 +/- 19.2 kg, respectively, at the initiation of renal replacement therapy. Overall treatment mortality rate was 57.2% (12 of 21 treatments), with 11 of the 18 patients (61.1%) dying before hospital discharge. Two-year follow-up on those patients demonstrated that 5 patients (71.4%) remained alive. Initial therapy with hemodialysis was associated with improved survival. Ten treatments (47.6%) required transition to another form of renal replacement therapy to maintain ongoing metabolic control, with a mean duration of 6.1 +/- 9.8 days. Time to renal replacement therapy >24 hours was associated with an increased risk of mortality, whereas a blood pressure >5th percentile for age at the initiation of therapy and the use of anticoagulation were associated with a decreased risk of mortality.


CONCLUSIONS
Renal replacement therapy can correct the metabolic disturbances that accompany suspected or confirmed inborn errors of metabolism. Our experience demonstrates an approximately 60% mortality rate associated with renal replacement treatment, with more than 70% of survivors living longer than 2 years.
McBryde
Kevin D
KD
Department of Nephrology, Children's National Medical Center, Washington, DC 20010, USA. KMCBRYDE@cnmc.org
Kershaw
David B
DB
Bunchman
Timothy E
TE
Maxvold
Norma J
NJ
Mottes
Theresa A
TA
Kudelka
Timothy L
TL
Brophy
Patrick D
PD
D000138:Acidosis / Q000209:etiology / Q000628:therapy; D058186:Acute Kidney Injury / Q000209:etiology / Q000628:therapy*; D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D022124:Hyperammonemia / Q000209:etiology / Q000628:therapy; D033461:Hyperuricemia / Q000209:etiology / Q000628:therapy; D007022:Hypotension / Q000209:etiology; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008661:Metabolism, Inborn Errors / Q000150:complications / Q000401:mortality / Q000628:therapy*; D017582:Renal Replacement Therapy; D012189:Retrospective Studies; D012307:Risk Factors; D016019:Survival Analysis